REG - Avacta Group PLC - Avacta Appoints Chief Financial Officer

AvactaAnnouncement

13/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250113:nRSM0551Ta&default-theme=true

RNS Number : 0551T  Avacta Group PLC  13 January 2025

Avacta Appoints Brian Hahn as Chief Financial Officer

 

-     Brian brings 25 years' senior financial and operational experience,
including leading GlycoMimetics' Nasdaq IPO and financial operations

 

LONDON and PHILADELPHIA - Jan 13, 2025 - Avacta Therapeutics (AIM: AVCT), a
life sciences company developing next generation peptide drug conjugates (PDC)
targeting powerful anti-tumor payloads directly to the tumor, today announced
the appointment of Brian Hahn as Chief Financial Officer (CFO).

 

Mr Hahn brings more than 25 years of senior financial and operations
experience in the biopharmaceutical industry, including a 15-year tenure as
CFO and Senior Vice President of GlycoMimetics, Inc., where he led the
company's 2014 initial public offering (IPO) on Nasdaq and the build-out of
its finance, accounting, investor relations and corporate affairs functions.

 

He has worked with life science companies from early stages through product
launch, has significant experience in dealing with US healthcare investors,
having been involved in multiple IPOs and has raised over $700 million in
capital. He has broad experience in developing strategic plans, business
development deals, building strong organizations and establishing strong
accounting and control systems which ensure Sarbanes-Oxley compliance.

 

Mr Hahn currently serves as co-chairman of the BIO Finance and Tax Committee,
as a co-chairman of the Steering Committee of the Washington, DC chapter of
the Association for Bio Financial Officers (ABFO) and has also served on the
Securities and Exchange Commissions' Advisory Committee on Small and Emerging
Companies. Prior to his 15-year tenure at GlycoMimetics, Mr. Hahn held roles
of increasing financial leadership responsibility, including Executive
Director of Finance at MiddleBrook Pharmaceuticals (formerly Advancis
Pharmaceutical), and earlier, Senior Accountant with Bering Truck Corporation.

 

He received a B.B.A. in Accounting from Shenandoah University and an M.B.A.
from the University of Maryland.

 

"Brian brings the ideal combination of deep public company experience and
understanding of the biotechnology sector that Avacta needs at this
transformative stage," said Christina Coughlin, M.D., Ph.D., Chief Executive
Officer of Avacta. "His strategic insight and track record of successful
financial leadership in clinical-stage companies will be essential as we
advance our promising pipeline and prepare for our next phase of growth,
including our potential dual listing on the Nasdaq exchange."

 

"What drew me to Avacta was not just the company's innovative technology
platforms. It also has a clear vision for revolutionizing cancer treatment
through targeted therapies that improve outcomes for patients and their
families," commented Brian Hahn. "The company has built a strong foundation
with its pre|CISION(®) and Affimer(®) platforms, and I look forward to
leveraging my experience to help accelerate Avacta's growth and strengthen its
position in both the U.K. and U.S. capital markets."

 

 

 

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                    www.avacta.com (http://www.avacta.com/)

 Michael Vinegrad, Group Communications

 Director

 Peel Hunt (Nomad and Broker)

 James Steel / Chris Golden / Patrick Birkholm       www.peelhunt.com (http://www.peelhunt.com/)

 ICR Healthcare

 Mary-Jane Elliott / Jessica Hodgson / Max Bennett   avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Investor Contact

 Renee Leck                                          renee@thrustsc.com (mailto:renee@thrustsc.com)

 THRUST Strategic Communications

 Media Contact

 Carly Scaduto                                       Carly@carlyscadutoconsulting.com

                                                   (https://www.globenewswire.com/Tracker?data=YG-jwixFWaHByFwlhEr4NbVmhGc9YbrV0ozbiHY-33jDG-KDtaZDvqBLS4-5RgIi5zejtwvrLPO1U6xSYlV9BnK-dIegbuZft6wwj-ugstEWYrPDSrd9NwgKYBdm1l9Ty6VSa1gsRJqxeLaMfUN-easXzPVocBafm0xbzTKFahId-T7w4WgPYGYfKdFh6MGXNNniX0b0LrpQwjqHYj_mTmjerN3nRW6pwlbWejQ6wZCns0oke-U-WA7CB-Z2CD1ObedcWrqwKYgQwTY1NxAOLXtmHTL3VJ7HZ4Z3K9ZhB_2_vgbo4aKKTppE6l1bjU2w)
 Carly Scaduto Consulting

 

 

About Avacta - www.avacta.com (http://www.avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary warhead delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent warheads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGZGMMZZKGKZZ